BUZZ-OncoMed Pharmaceuticals: Set to open at 3-mth low after equity raise

** OncoMed Pharmaceuticals down 15 pct premarketafter cancer drug developer prices its follow-on launched afterthe bell Wed at a steep discount

** If losses hold, stock set to open at lowest levels sinceearly May. On course for biggest one-day pct fall since Jan

** OncoMed offers 5.5 mln shares at $10.00, a 14.6-pctdiscount to stock's $11.71 last sale

** Deal represents about 18 pct of co's 30.84 mln sharesoutstanding as of end-Jun

** OncoMed expects to use offering proceeds along with cashon hand to fund its experimental immuno-oncology drug platform

** OMED has seven drug candidates in various stages ofdevelopment. Has collaboration agreements with top shareholderGlaxoSmithKline, as well as Bayer AG andCelgene

** YTD, OncoMed's stock has lost half its value, while theNasdaq Biotech index has shed 14 pct